ABSTRACT
Objective:To investigate the effects of aerosol therapy with budesonide suspension combined with compound ipratropium bromide on partial pressure of carbon dioxide (PaCO 2) and tumor necrosis factor α (TNF-α) in children with bronchiolitis. Methods:A total of 124 children with bronchiolitis admitted to Gujiao Central Hospital from January 2019 to December 2021 were included in this study. These children were randomly divided into two groups using the coin-tossing method. The control group ( n = 62) was treated with routine symptomatic treatment, and the study group ( n = 62) was treated with aerosol therapy of budesonide suspension combined with compound ipratropium bromide based on routine symptomatic treatment. The time at which clinical symptoms disappear, clinical efficacy, inflammatory reaction, and blood gas index were determined in each group. Results:After treatment, the time at which asthma, cough, pulmonary rales, and fever in the study group were (2.28 ± 0.71) days, (3.30 ± 0.82) days, (5.25 ± 1.03) days, and (19.01 ± 2.65) hours, respectively, which were significantly shorter than (2.71 ± 0.89) days, (3.81 ± 0.98) days, (5.72 ± 1.37) days, and (20.76 ± 3.12) hours in the control group ( t = 2.97, 3.14, 2.15, 3.36, all P < 0.05). Total response rate and PaO 2 in the study group were 91.94% and (83.94 ± 4.02) mmHg, respectively, which were significantly higher than 77.42% and (81.25 ± 5.53) mmHg in the control group ( χ2 = 5.03, t = 3.09, both P < 0.05). Interleukin-18, interleukin-33, TNF-α, and PaCO 2 in the study group were (141.03 ± 34.69) ng/L, (143.87 ± 38.43) ng/L, (75.49 ± 18.43) ng/L, and (41.85 ± 3.31) mmHg, respectively, which were significantly lower than (158.64 ± 47.92) ng/L, (162.75 ± 50.32) ng/L, (83.22 ± 21.75) ng/L, and (43.58 ± 4.46) mmHg in the control group ( t = -2.34, -2.34, -3.23, -2.45, all P < 0.05). Conclusion:Aerosol therapy with budesonide suspension combined with compound ipratropium bromide based on routine symptomatic treatment is more effective on bronchiolitis than routine symptomatic treatment alone. The combined therapy can effectively decrease PaCO 2 and TNF-α levels.
ABSTRACT
@#Objective To evaluate the effect of perioperative nebulization of ipratropium bromide on preoperative pulmonary function and incidence of postoperative pulmonary complications as well as safety in chronic obstructive pulmonary disease (COPD) patients who underwent lung resection in thoracic surgery. Methods During November 18, 2013 to August 12, 2015, 192 COPD patients with a necessity of selective surgical procedures of lobectomy or right bilobectomy or segmentectomy under general anaesthesia in 10 centers were 1 : 1 randomized to an ipratropium bromide group (96 patients) and a placebo group (96 patients), to compare the effect on preoperative pulmonary function and incidence of postoperative pulmonary complications. The average age of treated patients was 62.90±6.50 years, with 168 male patients and 22 female patients. Results The demographic and baseline characteristics were well-balanced between the two groups. The adjusted mean increase of forced expiratory volume in one second (FEV1) in the ipratropium bromide group was significantly higher than that in the placebo group (169.90±29.07 mL vs. 15.00±29.35 mL, P<0.05). The perioperative use of ipratropium bromide significantly decreased incidence of postoperative pneumonia (2.6% vs. 14.1%, P<0.05). There was no ipratropium bromide related adverse event (AE) observed in this trial. Conclusion This trial indicates that perioperative nebulization of ipratropium bromide significantly improves preoperative lung function and reduces postoperative pneumonia in COPD patients undergoing lung resection in thoracic surgery, and has good safety profile.
ABSTRACT
Background: The objective of the study was to compare the efficacy between levosalbutamol and ipratropium combination over levosalbutamol nebulisation in reversing airflow obstruction and improve oxygenation, evaluated using the pulmonary asthma score, SaO2, and PEFR in mild and moderate asthma.Methods: A prospective, randomized, study was performed in RMMCH pediatric emergency department. Children between 6 and 12 years of age who presented with mild to moderate asthma exacerberations were enrolled in the study. They were randomly allocated into two different groups: one nebulised with levosalbutamol alone and another with addition of ipratropium bromide to levosalbutamol. Baseline Peak expiratory flow rate and Final absolute values or change from baseline 60-120 minutes after the inhalation are measured. Patients were evaluated using the pulmonary score.Results: After treatment there is improvement in the mean pulmonary asthma scores and PEFR percentage in A+B group than A group, but it is not statistically significant (p value >0.05). There is statistically significant improvement in pulmonary asthma score and PEFR in each of the groups after nebulisation and pulmonary asthma score has a sensitivity of 66.7% and 65.6% in diagnosing severity of asthma in relation to PEFR.
ABSTRACT
Introduction:Asthma is a chronic inflammatory condition of the lung airways resulting in episodic airflow obstruction. This chronic inflammation heightens the airway hyper responsiveness (AHR). Asthma is defined by the history of respiratory symptoms like wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity together with variable expiratory airflow limitation.1 Aims & Objectives: To compare the effectiveness of a combination of inhaled anticholinergics (ipratropium bromide) and beta 2 agonists (salbutamol) compared with beta 2 agonists (salbutamol) alone for the treatment of children with acute exacerbation of asthma. Methods: This is a randomized comparative study conducted in the Department of pediatrics ASRAM Medical College during the period May 2018 to June2019. Total 66 children between the age group of 1-15 years with eligible diagnostic criteria were included in the study. Results: The percentage increase in predicted PEFR is better in Group II with a mean of 24.74 compared to Group I with a mean of 13.35. The p value is highly significant 0.001. The mean PAS at the start of the study is 10.5 in Group I and 10.7 in Group II. The mean PAS at the end of the study is 7.19 in Group I and 5.77 in Group II. The p value is 0.001 and is highly significant. The outcome is better in Group II when compared to Group I with a better decrease in PAS and better increase in percentage predicted PEFR. Conclusion: In the present study it has been proven the repeated doses of Ipratropium bromide combined to Salbutamol is beneficial and it reduces the broncomotor cholinergic tone.
ABSTRACT
Objective To study and explore the application effect of compound ipratropium bromide combined with budesonide in acute severe asthma.Methods 100 emergency patients with severe asthma were selected as study subjects,the patients were divided into two groups by following the principles of randomized single blind,each group had 50 cases.The control group received aminophylline treatment,the observation group was treated with budesonide combined with ipratropium bromide inhalation therapy.The clinical curative effect,relieve symptoms,condition of arterial blood gas and pulmonary function were compared between the two groups.Results The total effective rate of the observation group was 96％,which of the control group was 80％,the difference was statistically significant (x2 =6.061,P ＜ 0.05).The remission time of cough [(5.60 ± 1.35) d],expectoration [(3.54 ± 1.25) d],shortness of breath[(1.93 ± 0.87) d],wheezing [(6.09 ± 1.26) d] and other symptoms in the observation group were significantly shorter than those in the control group [(7.39 ± 1.72) d,(5.17 ± 1.54) d,(3.26 ± 1.08) d,(8.43 ±1.95) d](t =5.789,5.811,6.781,7.127,all P ＜ 0.05).After treatment,the arterial blood gas and lung function in the observation group were significantly improved (all P ＜ 0.05),which were better than those in the control group after treatment (all P ＜ 0.05).Conclusion The clinical curative effect of budesonide combined with ipratropium bromide in the treatment of patients with severe asthma is significant,it can improve the symptoms,pulmonary ventilation function and arterial blood gas.
ABSTRACT
OBJECTIVE:To investigate the effects of aerosol inhalation of budesonide combined with Compound ipratropium bromide on therapeutic efficacy and safety of patients with pneumoconiosis during perioperative period of massive whole-lung la-vage (WLL). METHODS:One hundred and fifty male patients with pneumoconiosis receiving WLL under general anesthesia se-lected from our hospital during Dec. 2014-May 2016 were divided into treatment group and control group in accordance with ran-dom number table,with 75 cases in each group. Both groups received WLL under general anesthesia as well as pure-oxygen manu-al positive pressure ventilation alternating with negative pressure drainage keeping interval and respiratory rate of ventilator synchro-nization. Treatment group was given Budesonide suspension 2 mL,bid+ Compound ipratropium bromide solution 2.5 mL,tid,by aerosol inhalation from 3 d before surgery to 3 d after surgery. The levels of arterial blood gas indexes(pH,PaO2,PaCO2,BE)at different lavage stages,lung function indexes (FVC,MVV,FEV1/FVC),blood gas indexes and clinical symptom score 3 d be-fore surgery and 7 d after surgery were observed in 2 groups,and the occurrence of ADR was recorded. RESULTS:After two-lung ventilation for 20 min following unilateral/bilateral lung lavage,PaO2 of 2 groups were all increased significantly compared to be-fore surgery,with statistical significance (P0.05). three days after surgery,FVC,MVV,FEV1/FVC and PaO2 of 2 groups were all increased significantly,PaCO2 and clinical symptom score were all decreased significantly. FVC,FEV1/FVC,PaO2 and clinical symptom score of treatment group were significantly bet-ter than those of control group,with statistical significance(P<0.05). The incidence of airway spasm,hypoxemia and airway pres-sure increasing in treatment group were significantly lower than in control group,with statistical significance(P<0.05). CONCLU-SIONS:During perioperative period of WLL,the aerosol inhalation of budesonide combined with Compound ipratropium bromide for patients with pneumoconiosis can improve clinical efficacy of WLL and reduce the occurrence of ADR during surgery.
ABSTRACT
Objective To analyze the clinical efficacy of ipratropium bromide combined with terbutaline sulfate inhalation in the treatment of acute attack of asthma. Methods 100 patients with acute attack of asthma treated from March 2015 to October 2016 were selected and randomly divided into the control group and the experimental group, with 50 patients in each group. The control group received terbutaline sulfate inhalation, and the experimental group received ipratropium bromide combined with terbutaline sulfate inhalation treatment. The patients in the experimental group and the control group were treated for 7 days continuously. The therapeutic effects of the two groups were compared and analyzed. Results After the corresponding treatment, the effective rate of treatment in the experimental group (94.0%) was significantly higher than that in the control group (72.0%),the difference was statistically significant(P<0.05). The improvement time of dyspnea, rale and cough in control group was significantly longer than that in the experimental group, the difference was statistically significant(P<0.05). Conclusion Ipratropium bromide combined with terbutaline sulfate inhalation in the treatment of acute attack of asthma has better clinical efficacy and shorter clinical symptoms.
ABSTRACT
Objective To analyze the clinical efficacy of ipratropium bromide combined with terbutaline sulfate inhalation in the treatment of acute attack of asthma. Methods 100 patients with acute attack of asthma treated from March 2015 to October 2016 were selected and randomly divided into the control group and the experimental group, with 50 patients in each group. The control group received terbutaline sulfate inhalation, and the experimental group received ipratropium bromide combined with terbutaline sulfate inhalation treatment. The patients in the experimental group and the control group were treated for 7 days continuously. The therapeutic effects of the two groups were compared and analyzed. Results After the corresponding treatment, the effective rate of treatment in the experimental group (94.0%) was significantly higher than that in the control group (72.0%),the difference was statistically significant(P<0.05). The improvement time of dyspnea, rale and cough in control group was significantly longer than that in the experimental group, the difference was statistically significant(P<0.05). Conclusion Ipratropium bromide combined with terbutaline sulfate inhalation in the treatment of acute attack of asthma has better clinical efficacy and shorter clinical symptoms.
ABSTRACT
Owing to the increasing morbidity and pulmonary infection,management of pulmonary function has become an important problem for COPD patients who undergo surgery.Surgical patient with respiratory disease such as COPD has declined lung function before operation,then increased the risk of post-operative pulmonary complications.Ipratropium bromide can significantly improve pulmonary function.Therefore,we hypothesis the treatment with nebulized ipratropium bromide will benefit the perioperative patients with COPD.A randomized,double-blind,placebo-controlled,parallel-group,multi-center trial (Ipratropium bromide in Peri-Operative COPD study,IPO-COPD study)has been conducted to evaluate the efficacy and safety of nebulized ipratropium bromide in Chinese perioperative patients with COPD under general anaesthesia.A total of 192 COPD patients who satisfied the eligibility criteria were randomly assigned(1∶1) to one of the two treatment groups(ipratropium bromide 500 μg or normal saline 4 ml) for 11 days.Measurements will include the change of the forced expiratory volume in 1 second(FEV1),the forced vital capacity(FVC),blood gas analyses and main post-operative pulmonary complications.
ABSTRACT
Objective To investigate the therapeutic effect of ipratropium bromide on bronchial spasm of patients with asthma and chronic obstructive pulmonary disease (COPD).Methods 174 patients with asthma and COPD were selected and divided into two groups, 87 cases in the control group treated with budesonide and formoterol fumarate powder for inhalation , 87 cases in the experimental group received ipratropium bromide on the basis of the control group, pulmonary ventilation function, airway resistance and cytokine levels in induced sputum, the clinical effect and incidence of adverse reactions were compared after the treatment.Results The effective rate in the control group(81.61%)was lower than the experimental group (93.11%), with significant difference (P<0.05); compared with the control group, levels of peak expiratory flow (PEF), maximum midexpiratory flow (MMEF), forced expiratory volume in one second to forced vital capacity ratio (FEV1%), forced vital capacity (FVC) were higher in the experimental group after treatment, levels of airway resistance (Raw), Raw% were lower, level of specific airway conductance (Gsp) was higher after treatment, induced sputum levels of vascular endothelial growth factor (VEGF), intercellular adhesion molecular-1 (ICAM-1), interleukin-13 (IL-13), IL-17 were lower after treatment, with significant difference (P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups.Conclusion The clinical effect of ipratropium bromide in the treatment of asthma and COPD was exactly , ipratropium bromide can significantly improve the pulmonary ventilation function in patients, relieve bronchial spasm, reduce airway resistance, inhibit airway inflammation, and the safety is higher.
ABSTRACT
Objective To investigate the effect of ipratropium bromide combined with budesonide /formoterol fumarate inhalation powder on serum FeNO and lung function of bronchial asthma patients.Methods 102 cases with clear bronchial asthma during Jan 2013 and Mar.2015 from the affiliated Qianfo Hill Hospital of Shandong University were randomly divided into three groups, control group A (34 cases) were treated with ipratropium bromide, control group B (34 cases) were treated with budesonide/formoterol fumarate powder, experiment group (34 cases) were given ipratropium bromide combined with budesonide/formoterol fumarate powder, all groups were treated for 6 months.Pulmonary function, serum FeNO and IgE levels, clinical efficacy were compared after treatment.Results The effective rate of control group A, B (70.59%, 67.65%) were significantly lower than experiment group (91.18%), the difference were significant (P<0.05).FEV1, FVC, FEV1%pre of experiment group were significantly higher than control group A and B after the treatment.Serum IgE and FeNO concentration were significantly lower than control group A, B, the difference were significant ( P<0.05 ) .Conclusion Ipratropium bromide combined with budesonide/formoterol fumarate powder for inhalation in bronchial asthma patients can effectively reduce FeNO concentration, improve lung function.
ABSTRACT
OBJECTIVE:To investigate the safety and effects of different doses of budesonide combined with ipratropium bro-mide on rational symptom,lung function and arterial blood gas indexes of patients with acute exacerbation of chronic obstructive pulmonary diseases (AECOPD). METHODS:186 AECOPD inpatients were selected and randomly divided into low-dose,medi-um-dose and high-dose groups,with 61 cases in each group. All groups received routine treatment as ipratropium bromide 500 μg+0.9%Sodium chloride injection(NS)2 ml,oral inhalation with oxygen drive atomization nebulizer,oxygen flow rate of 4-5 L/min, 15-20 min/time,tid. Low-dose,medium-dose and high-dose group were additionally given Budesonide suspension 0.5,1.0,2.0 mg+NS 2 ml respectively,oral inhalation with oxygen drive atomization nebulizer,oxygen flow rate of 4-5 L/min 20 min/time,bid. Pa-tients in 3 groups were treated for 7 days. Pulmonary function,MRC score,arterial blood gas indexes and ADR were compared among 3 groups before treatment,3 and 7 days after treatment. RESULTS:FEV1% of 3 groups were significantly improved after treatment;3 and 7 days after treatment,FEV1% of high-dose group was higher than that of medium-dose and higher than that of low-dose group,with statistical significance(P0.05). After treatment,there was statistical significance in PaCO2 and PaO2 among 3 groups (P<0.05),and the improvement of high-dose group was better than those of medium-dose and better than that of low-dose group,with statistical significance(P<0.05). No severe ADR was found in 3 groups. CONCLU-SIONS:Aerosol inhalation of 2.0 mg budesonide combined with ipratropium bromide can effectively improve pulmonary function, rational symptoms and arterial blood gas indexes with good safety.
ABSTRACT
Objective To explore the clinical efficacy on hyperbaric oxygenation combined with 0.025% ipratropium bromide inhalation in treatment of patients with stable chronic obstructive pulmonary disease( COPD) .Methods 86 elderly patients with stable COPD were divided into control group (n=42)and observation group(n=44)according to therapeutic methods.The patients in both groups were firstly given the conventional treatment such as oxygen inhalation, anti-infection, eliminating phlegm and reliving asthma, nutritional support, spasmolysis as well as a balance of water, electrolyte and PH.And the patients of the observation group were given hyperbaric oxygenation combined with 0.025% ipratropium bromide inhalation on basis of the conventional treatment.The clinical effects of the two groups were compared.Results In the control group, there were no statistical differences in parameters of pulmonary function before and after the treatment.However, after treatment, the relative index level of pulmonary function in the observation group was significantly higher than that of pre-treatment and that of the control group after treatment(P<0.05).After treatment, PaO2, SaO2 and pH of the two groups were significantly higher than those of pre-treatment(P<0.05).The level of PaCO2 in the two groups was significantly lower than that of pre-treatment(P<0.05).Also, the difference in PaO2, PaCO2 and SaO2 level was statistically significant before and after treatment between thw two groups(P<0.05).The scores of each dimension in PSQI scale of both groups were significantly lower than those of pre-treatment(P<0.05).And the scores of each dimension in PSQI scale of observation group was significantly lower than those of the control group after treatment(P<0.05).Whole blood cholinesterase activity of both groups was obviously greater than before treatment between theo two groups(P<0.05).Serum creatinine level of both groups were obviously lower than those of pre-treatment(P<0.05),and the differences in two groups in both blood cholinesterase activity and serum creatinine level were statistically significant ( P<0.05 ) .Conclusion The combination of high pressure oxygen and 0.025%ipratropium bromide for patients with stable COPD has a very significant clinical efficacy.It can effectively improve cholinesterase activity and lower serum creatinine level.
ABSTRACT
Abstracts: Background: This study compared the efficacy of levosalbutamol alone and ipratropium bromide alone with levosalbutamol and ipratropium bromide combined, through inhalational route in stable patients of chronic obstructive pulmonary disease (COPD). The study was carried out in 102 patients of COPD. Levosalbutamol inhalation was administered to 33 patients and ipratropium bromide inhalation was given to 31 patients.38 patients were treated with combination of levosalbutamol and ipratropium bromide inhalation. Pulmonary functions were noted before and after 15, 30, 60,120,180 and 240 minutes of inhalation of these drugs. Bronchodilation was significantly more in patients treated with combination therapy as compared to patients treated with single drug separately. The effect was more sustained in combination therapy as it started declining after 120 minutes with levosalbutamol, after 180 minutes in ipratropium bromide and after 240 minutes with combination therapy. So it was concluded that combination therapy with levosalbutamol and ipratropium bromide is better in management of COPD patients than using either of agents alone.
ABSTRACT
Objective To explore the effect of ipratropium bromide on serum interleukin-13 (IL-13), transforming growth factor-β1 (TGF-β1) and vascular endothelial growth factor (VEGF) in children with asthma.Methods Eighty-six children with asthma in pediatrics department of Hanggang Hospital from January 2014 to June 2014 were selected and divided into two groups according to different therapy, 43 cases in each group.Control group received aminophylline of intravenous drip infusion and salbutamol and ketotifen orally.Experimental group received ipratropium bromide of aerosol inhalation on the basis of control group, twice daily and treated for two courses, 7 days of one course.The clinical efficacy , serum IL-13, TGF-β1, VEGF and lung function post-treatment were compared between two groups.Results The total curative effect of experimental group was 90.69%, which was significantly higher than 72.09% of control group(χ2 =4.91,P<0.05).The serum levels of IL-13, TGF-β1 and VEGF after 3, 7 and 14 days’ treatment in two groups were lower than those pre-treatment(P<0.05).The above indicators of experimental group were lower than those of control group at the same time point(P<0.05).The FEV1 and FEV1/FVC% after 7, 14 days’ treatment in control group and the above indicators after 3, 7, 14 days’ treatment in experimental group were significantly higher than those pre-treatment (P<0.05).The above indicators of experimental group were higher than those of control group at the same time point (P<0.05).Conclusion Ipratropium bromide could affect serum IL-13, TGF-β1 and VEGF levels in children with asthma, improve lung function and clinical curative effect.
ABSTRACT
Objective To explore the effect of budesonide combined with ipratropium bromide in the treat-ment of acute exacerbations of chronic obstructive pulmonary disease,and observe the adverse reactions during treat-ment.To analyze the treatment of safety and to provide the basis for clinical treatment.Methods 160 cases of acute exacerbations of chronic obstructive pulmonary disease were selected,they were randomly divided into the control group A,B,C and the observation group,with 40 cases in each group.The control group A was treated with prednisone and other conventional,control group B was treated with aminophylline and other conventional treatment,the control group C application included prednisone,aminophylline and other conventional treatment,all the control group were treated with 0.9% sodium chloride solution inhaled as a placebo spray.And the observation group application of budesonide was combined with ipratropium bromide based on the routine treatment.Mainly the effect of treatment was observed,and the blood carbon dioxide partial pressure (PaO2 ),partial pressure of oxygen (PaCO2 ),forced expiratory volume in one second (FEV1 ),forced expiratory volume in one second (FEV1 )and forced expiratory volume in one second to forced vital capacity ratio of FVC (FEV1 /FVC)before and after treatment were detected.And the adverse reactions were observed to evaluate its safety.Results The total effective rate of the observation group was 95.00%(38 /40),which were higher than the control group A,B and C,the differences were statistically significant (χ2 =9.68,9.70,9.91,all P 0.05). Conclusion It has good clinical curative effect on budesonide combined with ipratropium bromide for the treatment of acute exacerbations of chronic obstructive pulmonary disease patients,which can significantly improve the pulmona-ry function of patients,shorten recovery time,and has high security.It is worthy of clinical application.
ABSTRACT
Objective:To investigate the clinical effects and safety of triple therapy based on ipratropium bromide inhalation in the treatment of acute exacerbation of chronic obstructive pulmonary diseases ( AECOPD) . Methods:Totally 150 patients with acute exac-erbation of AECOPD were randomly divided into control group (75 patients) treated with budesonide combined with salbutamol by in-halation, and treatment group (75 patients) treated with ipratropium bromide inhalation additionally. The clinical effects, dyspnea score, pulmonary function index and blood gas analysis index before and after the treatment and the incidence of adverse reactions of the two groups were compared. Results:The clinical effects of the treatment group was significantly better than that of the control group (P0. 05). Conclusion:Triple therapy including ipratropium bromide inhalation in the treatment of acute exacerbation of AECOPD can ef-fectively alleviate clinical symptoms and signs and improve the lung ventilation function without increased risk of adverse reactions.
ABSTRACT
Objective To observe the effect and the influence on PCT,CRP in the treatment of patients with acute exacerbation pulmonary disease by Budesonide and ipratropium bromide.Methods 80 patients with acute exacerbation pulmonary disease were randomly divided into 40 cases of the control group and 40 cases of the observa-tion group,the two groups were given routine treatment,the control group then had been given ipratropium bromide for 7d,and the observation group had been given Budesonide and ipratropium bromide for 7d,the blood gas indicators (PaO2 ,PCO2 ),pulmonary function (FEV1 ,PEF,FEV1 /FVC),dyspnoea and exercise tolerance score,serum PCT levels,serum CRP levels and clinical efficacy were compared,Adverse reactions were recorded.Results (1 )the PaO2 ,FEV1 ,PEF,FEV1 /FVC of the observation group and the control group after treatment were (70.7 ±2.3)mmHg and (62.5 ±3.0)mmHg,(2.15 ±0.63)L and (1.76 ±0.56)L,(3.49 ±0.82)L/s and (3.06 ±0.75)L/s, (68.52 ±6.53)% and (60.14 ±6.03)%,These indicators were significantly higher than those before treatment,all P <0.05,the PCO2 ,PCT,CRP were (51.4 ±1.7)mmHg and (56.6 ±2.3)mmHg,(1.75 ±1.20)μg/L and (2.58 ± 1.17)μg/L,(10.25 ±6.77)mg/L and (19.07 ±5.75)mg/L,These indicators were significantly lower than those before treatment,all P <0.05,the PaO2 ,FEV1 ,PEF,FEV1 /FVC of the observation group were significantly higher than those of the control group,the PCO2 ,PCT,CRP were significantly lower than those of the control group,all P <0.05;(2)The dyspnoea and exercise tolerance score of the observation group and the control group after treatment was significantly lower than those before treatment,the dyspnoea and exercise tolerance score of the observation group was significantly lower than those of the control group;(3)The clinical total effective rate of the observation group was 90%,which was higher than 65% of the control group(χ2 =7.312,P <0.05).Conclusion The method containing Budesonide and ipratropium bromide Inhalation has exact effect,and can effectively improve respiratory function, which is an effective treatment of choice for acute exacerbation of COPD.
ABSTRACT
This study was aimed to investigate the clinical effect of tetramethylpyrazine in combination with ipratropium bromide in the treatment of bronchial asthma and its effects on inflammatory factors and leptin. According to inclusion criteria, a total of 124 bronchial asthma cases were included and randomly divided into two groups, which were the control group (n = 62) and the observation group (n = 62) with the random number table. Besides conventional treatments, the control group was given ipratropium bromide; while the observation group was given tetramethylpyrazine in combination with ipratropium bromide. Then, comparisons were made between two groups on the therapeutic efficacy rate, pulmonary function, inflammatory factor, leptin, and incidence of adverse reactions. The results showed that the total therapeutic efficacy rate was 96.8% in the observation group, which was obviously higher than that of 87.1% in the control group (P 0.05). It was concluded that tetramethylpyrazine in combination with ipratropium bromide was effective for bronchial asthma treatment, which can significantly increase curative efficacy, improve pulmonary function, alleviate inflammatory reaction and reduce leptin level with minor adverse reactions. It required further studies in the clinical practice.
ABSTRACT
Aims: The aim of the current study was to establish a simple and yet as much as possible physiologic approach for a simulation of the pulmonary absorption process to compare different inhaled drugs or drug formulations. Methodology: We designed a dialysis setting that allowed monitoring the drug release from human lung tissue into a continuous-flow plasma compartment. For proof-of-concept experiments we chose the glucocorticoid fluticasone propionate (FP) as model compound. For subsequent experiments we selected a commercially available metered dose inhaler delivering a fixed combination of the short-acting ß2-agonist fenoterol and the muscarinic antagonist ipratropium bromide. Results: With the novel dynamic dialysis model we observed high drug transport rates from the lung tissue into plasma including an elimination phase. The concentration profile in the plasma compartment of our model system was similar to the plasma concentration courses after inhalation of FP. Compared to FP significantly higher drug fractions of fenoterol and ipratropium bromide were released into plasma and the transfer of ipratropium was more pronounced compared to fenoterol. Again, concentration profiles in plasma were alike to those described in clinical studies. Conclusion: We suggest that this model is appropriate for rapid assessment of comparative diffusion behaviour of drugs or drug formulations from lung tissue into plasma.